TR201809537T4 - Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. - Google Patents

Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. Download PDF

Info

Publication number
TR201809537T4
TR201809537T4 TR2018/09537T TR201809537T TR201809537T4 TR 201809537 T4 TR201809537 T4 TR 201809537T4 TR 2018/09537 T TR2018/09537 T TR 2018/09537T TR 201809537 T TR201809537 T TR 201809537T TR 201809537 T4 TR201809537 T4 TR 201809537T4
Authority
TR
Turkey
Prior art keywords
disease
group
ataxia
hydroxypyridazin
ataxic
Prior art date
Application number
TR2018/09537T
Other languages
English (en)
Turkish (tr)
Inventor
Almond Sarah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50554599&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201809537(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of TR201809537T4 publication Critical patent/TR201809537T4/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TR2018/09537T 2014-03-06 2015-03-06 Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri. TR201809537T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1403944.0A GB201403944D0 (en) 2014-03-06 2014-03-06 New use

Publications (1)

Publication Number Publication Date
TR201809537T4 true TR201809537T4 (tr) 2018-07-23

Family

ID=50554599

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/09537T TR201809537T4 (tr) 2014-03-06 2015-03-06 Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri.

Country Status (32)

Country Link
US (1) US20170014407A1 (enExample)
EP (1) EP3113778B1 (enExample)
JP (1) JP6510549B2 (enExample)
KR (1) KR20160126081A (enExample)
CN (1) CN106102743A (enExample)
AU (1) AU2015225954B2 (enExample)
CA (1) CA2940342A1 (enExample)
CL (1) CL2016002151A1 (enExample)
CY (1) CY1120573T1 (enExample)
DK (1) DK3113778T3 (enExample)
EA (1) EA036438B1 (enExample)
ES (1) ES2676905T3 (enExample)
GB (1) GB201403944D0 (enExample)
GE (1) GEP20196984B (enExample)
HR (1) HRP20181082T1 (enExample)
IL (1) IL247435A0 (enExample)
LT (1) LT3113778T (enExample)
MA (1) MA39315A1 (enExample)
MX (1) MX2016010524A (enExample)
MY (1) MY202127A (enExample)
PH (1) PH12016501751A1 (enExample)
PL (1) PL3113778T3 (enExample)
PT (1) PT3113778T (enExample)
RS (1) RS57594B1 (enExample)
SG (1) SG11201607106YA (enExample)
SI (1) SI3113778T1 (enExample)
SM (1) SMT201800367T1 (enExample)
TR (1) TR201809537T4 (enExample)
TW (1) TW201534591A (enExample)
UA (1) UA123352C2 (enExample)
WO (1) WO2015132608A1 (enExample)
ZA (1) ZA201604611B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201222711D0 (en) 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US10118917B2 (en) 2014-04-29 2018-11-06 E I Du Pont De Nemours And Company Pyridazinone herbicides
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
US11213030B2 (en) 2017-06-30 2022-01-04 Fmc Corporation 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides
CN112569217B (zh) * 2019-09-30 2022-04-22 厦门大学 戊酸衍生物在治疗遗传性小脑共济失调中的应用
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
CA3209781A1 (en) 2021-03-01 2022-09-09 Takeda Pharmaceuticals Company Limited Use of luvadaxistat for the treatment of cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321553T1 (de) * 1998-06-10 2006-04-15 Meiji Seika Kaisha Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
WO2003047558A2 (en) * 2001-12-03 2003-06-12 Genset S.A. Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors
JO3115B1 (ar) * 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao

Also Published As

Publication number Publication date
CA2940342A1 (en) 2015-09-11
EA036438B1 (ru) 2020-11-11
SMT201800367T1 (it) 2018-09-13
GB201403944D0 (en) 2014-04-23
JP6510549B2 (ja) 2019-05-08
MA39315A1 (fr) 2017-09-29
AU2015225954B2 (en) 2020-06-18
RS57594B1 (sr) 2018-11-30
SG11201607106YA (en) 2016-09-29
TW201534591A (zh) 2015-09-16
PL3113778T3 (pl) 2018-11-30
KR20160126081A (ko) 2016-11-01
DK3113778T3 (en) 2018-07-30
JP2017507156A (ja) 2017-03-16
EP3113778B1 (en) 2018-06-06
ES2676905T3 (es) 2018-07-26
LT3113778T (lt) 2018-08-27
AU2015225954A1 (en) 2016-07-07
GEP20196984B (en) 2019-06-25
MX2016010524A (es) 2016-10-31
CN106102743A (zh) 2016-11-09
SI3113778T1 (en) 2018-08-31
CL2016002151A1 (es) 2016-12-30
EA201691566A1 (ru) 2016-12-30
PH12016501751A1 (en) 2017-02-06
MY202127A (en) 2024-04-05
UA123352C2 (uk) 2021-03-24
IL247435A0 (en) 2016-11-30
PT3113778T (pt) 2018-07-11
WO2015132608A1 (en) 2015-09-11
ZA201604611B (en) 2017-09-27
EP3113778A1 (en) 2017-01-11
CY1120573T1 (el) 2019-07-10
HRP20181082T1 (hr) 2018-09-07
US20170014407A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
TR201809537T4 (tr) Ataksik bir hastalığın önlenmesi veya tedavi edilmesinde kullanım için piridazin türevleri.
US12201631B2 (en) Methods and compositions for reducing tactile dysfunction and anxiety associated with autism spectrum disorder, Rett syndrome, and fragile X syndrome
JP5605659B2 (ja) 細胞保護剤
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
JP6977029B2 (ja) レット症候群を治療するためのプリドピジンの使用
WO2008003511A1 (en) Use of aminothiazole derivative compounds, pharmaceutical compositions thereof, in the treatment of diseases characterized by abnormal repression of gene transcription, particularly huntington's disease
Downs et al. Blockade of M4 muscarinic receptors on striatal cholinergic interneurons normalizes striatal dopamine release in a mouse model of TOR1A dystonia
JP7340237B2 (ja) 色素性乾皮症及び色素性乾皮症に起因する症状の予防/改善剤
Barr et al. Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats
HK1230925A1 (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
US10034848B2 (en) Increase of protein synthesis ameliorates synaptopathy-related neurological disorders
AU2021359134A1 (en) Compositions and uses thereof
US20080318926A1 (en) Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives
Nigam et al. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions
Muniyasamy et al. A Behavioural and Histological Approach to Dose Dependent Chronic Toxicity Screening of Cyclotide in Zebrafishes.
WO2025042610A1 (en) Pifithrin analogues and methods of treating rett syndrome
EP4208161A1 (en) Compositions and uses thereof
Heinz et al. How much fear is in anxiety?
Thiele Striatal mechanisms mediating parkinsonism and L-DOPA-induced dyskinesia: Contribution of the direct-and indirect-output pathways
UA9407U (en) Method for treating diabetic retinopathy
Brumley The ontogeny of interlimb coordination during serotonin-induced hindlimb stepping in the perinatal rat